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ABSTRACT
 
Objectives:
 
Overactive bladder (OAB) is described as uri-
nary urgency, with and without urge incontinence and
usually with frequency and nocturia. Most attention to
OAB’s impact on health-related quality of life (HRQL),
however, has focused on urge incontinence. The objective
of this study was to evaluate the burden of OAB, specif-
ically urinary urgency and frequency on HRQL.
Methods: In the National Overactive Bladder Evaluation
Program (NOBLE), a computer-assisted telephone inter-
view survey was conducted to assess the prevalence of
OAB in the United States. Based on interview responses,
respondents were classiﬁed into three groups: continent
OAB, incontinent OAB, and controls. To evaluate the
HRQL impact of OAB, HRQL questionnaires were
mailed to all respondents with OAB and age- and sex-
matched controls as a performed nested case–control
study. Continuous data were compared using Student’s t
tests and analysis of variance with post hoc pairwise com-
parisons; results were adjusted for age, sex, and comorbid
conditions. Multivariable regressions were performed to
assess the impact of each urinary variable on symptom
bother and HRQL.
Results: A total of 919 participants responded to the
questionnaires (52% response rate) with a mean age of
54.2 years (SD 16.4 years); 70.4% were female and 85%
were white. Continent OAB participants comprised
24.8% of the sample, incontinent OAB 18.3%, and con-
trols 56.9%. In each regression analysis, urinary urge
intensity accounted for the greatest variance for increases
in symptom bother and decreases in HRQL.
Conclusions: The experience of urinary urgency has a
signiﬁcant negative effect on HRQL and increases symp-
tom bother, an effect that, in this community sample, is
greater than that of incontinence, frequency, or nocturia.
Keywords: overactive bladder, quality of life, symptoms,
urinary urgency.
 
Introduction
 
Urinary urgency (a sudden, compelling desire to uri-
nate, which is often difﬁcult to defer), with or with-
out urge incontinence, and usually with urinary
frequency and nocturia, can be described as “over-
active bladder” (OAB) [1]. Previous studies have
investigated the impact of OAB on health-related
quality of life (HRQL) to ﬁnd that urinary inconti-
nence has a negative impact on physical, social, and
psychological well-being and interferes with daily
activities [2–6]. Although the impact of urinary urge
incontinence  on  HRQL  has  been  widely  studied,
the effects of continent OAB symptoms, namely,
urgency and frequency, have not. The prevalence of
continent and incontinent OAB is estimated to be
16.6% or approximately 33 million men and
women in the United States [7] and 6% to 35% in
Europe [8]. The prevalence of continent OAB in the
United States is estimated to be 7.6% in women and
2.6% in men [7]. Given this, the impact of continent
OAB symptoms on HRQL warrants further
examination.
Although urge incontinence has received more
attention as a symptom of OAB, it is not the most
frequent symptom of OAB. Milsom et al. [8] found
urinary frequency and urgency to be reported more
frequently than urge incontinence. Robinson et al.
[9] found “number of voids/day” and “times awak-
ened at night” to be predictive of HRQL indicating
that other symptoms of OAB, not just incontinence,
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affect HRQL. In a sample of women seeking care
for troublesome symptoms at an urodynamic clinic,
Norton et al. [10] found that 34% of the women
were continent with symptoms of urgency, fre-
quency, and nocturia. Liberman et al. [11] evalu-
ated the impact of both continent and incontinent
OAB symptoms on HRQL in a population-based
survey and found that participants with symptoms
of continent OAB reported signiﬁcant decrements in
the mental health, health perception, and bodily
pain subscales of the Medical Outcomes Study (SF-
20) when compared to normal controls from the
survey. Thus, although the impact of incontinent
OAB on HRQL appears to be greater than conti-
nent OAB, continent OAB also appears to have
adverse effects on HRQL. The purpose of this study
was to investigate the impact of all OAB symptoms
on HRQL in a national community sample in the
United States.
 
Methods
 
Using a clinically validated computer-assisted tele-
phone interview (CATI), a national telephone sur-
vey was performed to estimate the prevalence of
OAB in the United States [7]. Quota sampling meth-
ods were used to ensure a representative US popu-
lation with respect to age, sex, and geographic
region. A total of 5204 people were surveyed and
the prevalence of OAB was 16% in men and 16.9%
in women [7]. As a follow-up to the national tele-
phone survey, a nested case–control study was con-
ducted among people meeting OAB case criteria
and age- and sex-matched controls who were
invited to complete a battery of self-administered
questionnaires related to HRQL, sleep, and depres-
sion. Institutional review board approval was
obtained before study initiation and all participants
provided informed verbal consent before data col-
lection was initiated.
The CATI survey included questions about
demographics, work status, childbearing history,
exercise, social activities, sleep habits, and ﬂuid
intake. Questions regarding the urinary symptoms
of frequency, urgency, nocturia, and urge or stress
incontinence as well as coping behaviors during the
4-week recall period preceding the telephone inter-
view were asked. To aid in differentiating diag-
nosis, questions regarding urinary symptoms
associated with urinary tract infections and pros-
tate problems as well as questions regarding other
physician-diagnosed comorbid conditions (e.g.,
congestive heart failure, diabetes) were also asked.
During the interview process, participants were
asked three questions regarding urgency: 1) “Did
you have a sudden and uncomfortable feeling that
you had to urinate soon?”; 2) “Did you have such
a strong urge to urinate that you had to stop what
you were doing and rush to the bathroom because
you might lose urine?”; and 3) “People sometimes
feel  a  sudden  urge  to  urinate.  Has  this
happened  to you in the past 4 weeks?” Partici-
pants who responded “yes” to any one of the three
questions were asked to rate their urge intensity on
a scale of 1 to 10 with 1 being “feel some urge, but
do not have to go right away” and 10 being “have
to stop what you are doing and urinate immedi-
ately.” Participants who responded “no” to experi-
encing urgency were scored as a “0” on the urge
intensity rating scale.
To avoid including participants with possible
metabolic or pathologic conditions that could
mimic OAB-like symptoms, cases were deﬁned
according to the telephone survey responses using
the following criteria:
1. Continent OAB cases included at least four epi-
sodes of urgency over the past 4 weeks plus
more than eight voids per day (waking hours)
or at least one bladder control coping behavior
(e.g., decreased ﬂuid intake, defensive voiding,
travel restricted to places with known bath-
room availability).
2. Incontinent OAB included the continent OAB
criteria, plus at least three episodes of urge
incontinence over the past 4 weeks.
These criteria were designed to optimize the sen-
sitivity and speciﬁcity of the clinicians’ diagnosis.
 
Nested Case–Control Study Questionnaires
 
Overactive  bladder  questionnaire  (OAB-q).
 
The
OAB-q consists of an 8-item symptom bother scale
and 25 HRQL items, which comprise four subscales
(coping, concern, sleep, and social interaction) and
a total HRQL score. The OAB-q is a clinically val-
idated OAB-speciﬁc HRQL instrument with dem-
onstrated high internal consistency and construct
and discriminant validity [12]. The symptom bother
and HRQL subscale scores and total HRQL score
are transformed to a 0 to 100 scale with higher
scores on the HRQL subscales indicating better
HRQL. Higher symptom bother scores indicate
greater symptom bother.
 
Medical outcomes study short-form 36 (SF-36).
 
The SF-36 is a self-administered generic health sta-
tus questionnaire that is composed of eight
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domains: physical function, role limitations-
physical, vitality, general health perception, bodily
pain, social function, role limitations-emotional,
and mental health. The SF-36 has been used exten-
sively as an indicator of HRQL with well-docu-
mented reliability and validity [13]. Lower scores
indicate poorer function.
 
Center for epidemiologic studies depression scale
(CES-D).
 
The CES-D is a 20-item scale that was
developed to assess depressive symptoms and has
demonstrated reliability and validity [14,15]. The
possible score range is from 0 (not at all depressed)
to 60 (very depressed) with a cutoff score of 21 as
an indicator of major depressive symptoms [16].
 
Medical outcomes study sleep scale (MOS-sleep).
 
The MOS-sleep scale is a self-administered 12-item
questionnaire that has been shown to be reliable
and valid [17,18]. This scale assesses various char-
acteristics of sleep including sleep disturbance, sleep
quality and duration, and restfulness. A higher
score on the MOS-sleep subscales is indicative of
poorer quality of sleep [19]. The Sleep Problems
Index I subscale, which consists of six items related
to sleep adequacy and disturbance, was used in this
analysis.
 
Statistical Analysis
 
All analyses were performed using SAS version
8.02 (SAS Institute, Inc., Cary, NC). Demo-
graphic variables and clinical conditions were
evaluated by descriptive analyses. Chi-square tests
were used to evaluate categorical data; 
 
t
 
 tests and
analyses of variance (ANOVA) were used to eval-
uate continuous data. To compare the HRQL and
symptom bother scores for normal controls, conti-
nent OAB, and incontinent OAB participants,
ANOVAs with post hoc pairwise comparisons
were performed; 
 
P
 
 values, however, were not
adjusted for multiple comparisons because this
examination of the data was considered explora-
tory. Adjustments for age, sex, and comorbid con-
ditions (i.e., diabetes, congestive heart failure,
prostate problems, previous bladder surgeries, his-
tory of cancer, number of births, and use of diu-
retics) were performed in the case–control
comparisons. A series of multivariable regression
models were performed to ascertain the effects of
urinary urge intensity, frequency episodes, number
of nocturia episodes, and number of incontinence
episodes on symptom bother and each of the
HRQL OAB-q subscales while controlling for age,
sex, and comorbid conditions. In the regression
models, all urinary variables and age were contin-
uous; all others were coded dichotomously. Multi-
collinearity was assessed using the variance
inﬂation factor (VIF) following the general rule
that the VIF should not exceed 10 [20]. In all
analyses, an alpha of 
 
<
 
0.05 was considered statis-
tically signiﬁcant.
 
Results
 
Of the 1769 OAB cases and age- and sex-matched
controls, 919 participants returned their question-
naires (52% response rate) (Table 1). Overall,
responders were more likely to be older, female, and
white with 57% of incontinent OAB participants,
60% of continent OAB participants, and 53% of
controls responding. Each group was representative
of participants in the CATI survey. Cases with
incontinent OAB were signiﬁcantly older and more
likely to be female than continent OAB participants
or controls. Comorbid conditions differed signiﬁ-
cantly by case/control status with incontinent OAB
cases reporting signiﬁcantly greater rates of diabe-
tes, congestive heart failure, use of diuretics, history
of bladder surgery, use of bladder medications, and
prostate problems (Table 2).
The symptom bother scores of the OAB-q were
signiﬁcantly higher and the HRQL subscales (con-
cern, coping, sleep, and social interaction) were
signiﬁcantly lower for the continent and  incon-
tinent OAB participants than normal controls
(
 
P 
 
<
 
 0.0001), even after adjusting for age, sex, and
comorbid conditions (Table 3). Additionally, incon-
tinent OAB participants, those with urge inconti-
nence in addition to frequency and urgency,
reported signiﬁcantly lower scores in all OAB-q sub-
scales and higher symptom bother scores than con-
tinent OAB participants (
 
P
 
 
 
<
 
 0.0001 for all). Similar
results were found among the SF-36 subscales. Sig-
niﬁcant differences were noted among continent and
incontinent OAB participants and controls; all
 
P
 
 
 
<
 
 0.001 except in the mental health subscale
where the difference between continent and incon-
tinent OAB participant scores was 
 
P
 
 
 
<
 
 0.05.
When examining the impact of urgency on
HRQL, signiﬁcant differences (
 
P
 
 
 
<
 
 0.0001) in all
OAB-q subscales were present between participants
who experienced urgency versus those who did not
(Table 4). For participants experiencing urgency,
43.4% reported CES-D scores 
 
≥
 
21, compared to
22.3% of those who did not experience urgency
(
 
P
 
 
 
<
 
 0.0001). Similar signiﬁcant differences were
noted in the Sleep Problems Index and SF-36 sub-
scale responses. Participants with urgency reported
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poorer sleep quality on the Sleep Problems Index
(
 
P
 
 
 
<
 
 0.0001) and decreased HRQL on all SF-36
subscales (
 
P
 
 
 
<
 
 0.0001). When examining respond-
ent ratings of urinary urge intensity with the ratings
divided into tertiles, signiﬁcant differences were
present among all three group ratings of urge inten-
sity on the OAB-q subscales (Fig. 1) (
 
P
 
 
 
<
 
 0.01). The
mean urge intensity rating was signiﬁcantly differ-
ent by case/control status with the mean equaling
1.5 for normal controls, 4.8 for continent OAB par-
ticipants, and 7.0 for incontinent OAB participants
(all pairwise comparisons, 
 
P
 
 
 
<
 
 0.0001). When com-
paring the urge intensity rating groups using the
generic questionnaires, signiﬁcant differences
(
 
P
 
 
 
<
 
 0.05) were apparent only between the lowest
and highest urgency rating groups in the Sleep Prob-
lems Index and in all SF-36 subscales; no differences
were present using the CES-D.
Urinary frequency of eight times or more per day
also had a signiﬁcant negative impact on HRQL
with signiﬁcantly (
 
P
 
 
 
<
 
 0.0001) reduced scores on all
OAB-q subscales and a signiﬁcant increase in symp-
tom bother compared to participants with urinary
frequency less than eight times per day (Table 5).
Urinary frequency appeared not to have as great an
impact on the SF-36 as did urgency. Signiﬁcant dif-
ferences (
 
P
 
 
 
<
 
 0.05) were noted in only three of the
subscales (general health, social function, and men-
tal health) when comparing respondents with fre-
quency of eight or more times with those with eight
or fewer times per day. Signiﬁcant differences
(
 
P
 
 
 
<
 
 0.01) were present in the Sleep Problems Index.
 
Table 1
 
Demographic characteristics
 
Characteristic
Control
(n 
 
=
 
 523)
Continent OAB
(n 
 
=
 
 228)
Incontinent OAB
(n 
 
=
 
 168)
 
P
 
 value
Age (mean years 
 
± 
 
SD) 52.2 (16.3) 54.3 (16.7) 60.0 (15.1)
 
<
 
0.0001*
Sex (n, % male) 178 (34.0) 146 (64.0) 40 (23.8)
 
<
 
0.0001
Race (n, %)
White 442 (84.5) 191 (83.8) 143 (85.1) 0.84
African American 37 (7.1) 20 (8.8) 15 (8.9)
Native American 7 (1.3) 3 (1.3) 1 (0.6)
Asian 3 (0.6) 3 (1.3) 0 (0.0)
Hispanic 13 (2.5) 5 (2.2) 6 (3.6)
Other 16 (3.0) 6 (2.6) 3 (1.8)
Missing 5 (1.0) 0 0
Marital status (n, %)
Married/living as married 304 (58.1) 137 (60.1) 92 (54.7) 0.13
Widowed 63 (12.0) 22 (9.6) 31 (18.5)
Divorced/separated 85 (16.3) 32 (14.0) 31 (18.5)
Never married 69 (13.2) 35 (15.4) 14 (8.3)
Missing 2 (0.4) 2 (0.9) 0
Education (n, %)
Less than high school 9 (1.7) 5 (2.2) 7 (4.2) 0.20
Some high school 35 (6.7) 21 (9.2) 18 (10.7)
High school graduate 175 (33.5) 83 (36.4) 61 (36.3)
Some college 144 (27.5) 65 (28.5) 41 (24.4)
College degree 122 (23.3) 39 (17.1) 27 (16.1)
Graduate degree 38 (7.3) 15 (6.6) 14 (8.3)
 
*Incontinent OAB vs. continent OAB and controls.
 
Table 2
 
Clinical characteristics
 
Clinical condition
Control
(n 
 
=
 
 523)
Continent OAB
(n 
 
=
 
 228)
Incontinent OAB
(n 
 
=
 
 168)
 
P
 
 value
Diabetes 34 (6.5) 21 (9.3) 34 (20.4)
 
<
 
0.0001
CHF 17 (3.3) 16 (7.1) 16 (9.5) 0.003
CNS disorder 6 (1.2) 10 (4.4) 13 (7.7)
 
<
 
0.0001
Interstitial cystitis 5 (1.0) 5 (2.2) 7 (4.2) 0.02
History of  bladder surgery* 10 (1.9) 36 (15.9) 36 (21.4) <0.0001
Prostate problems* (n 
 
=
 
 361) 26 (14.7) 32 (22.1) 21 (53.9)
 
<
 
0.0001
History of  cancer 38 (7.3) 23 (10.1) 25 (15.0) 0.01
Use of  bladder medications
 
†
 
4 (0.8) 11 (4.8) 32 (19.1)
 
<
 
0.0001
Use of  diuretics 52 (11.2) 35 (15.4) 48 (28.7)
 
<
 
0.0001
 
*Participant reports of  bladder surgery and prostate problems; no details provided.
 
†
 
Based on participant self-report and includes the following medications: antibiotics, cranberry pills, detrol, ditropan, tamsulosin hydrochloride, herbs, nitrofurantoin
monohydrate, oxybutynin, and “not sure.”
Abbreviations: CHF, congestive heart failure; CNS, central nervous system.
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Additionally, for those urinating eight or more times
per day, 36.5% had a CES-D score of 
 
≥
 
21 com-
pared to 28.8% urinating less than eight times per
day (
 
P
 
 
 
=
 
 0.03).
The presence of nocturia was related to decreases
in HRQL scores and increases in symptom bother
scores. Signiﬁcant HRQL differences (
 
P
 
 
 
<
 
 0.01)
were noted with increasing episodes of nocturia per
night in all OAB-q subscales except social interac-
tion. Additionally, for respondents who experienced
at least one episode of nocturia per night as few as
three nights per week, signiﬁcant (
 
P
 
 
 
<
 
 0.0001) dif-
ferences were seen in all OAB-q subscales when
compared to those who experienced no nocturia. Of
those experiencing nocturia one or more episodes
per night, 41.4% scored 
 
≥
 
21 on the CES-D versus
30.9% with nocturia one or no episodes per night
(
 
P
 
 
 
<
 
 0.01). Signiﬁcant differences (
 
P
 
 
 
<
 
 0.01) be-
tween respondents with more than one nocturia
episode versus those with one or no nocturia epi-
sodes were present on all SF-36 subscales and the
Sleep Problems Index.
In the six multivariable regression models with
each of the OAB-q subscales and total score as out-
comes, all of the urinary variables were signiﬁcantly
associated with each OAB-q subscale, except noc-
turia in the social interaction subscale. In each
model, urinary urge intensity had the highest 
 
F
 
value of all variables and greatest association with
decreases in HRQL and increases in symptom
bother. Tables 6 and 7 contain the parameter esti-
mates, standardized estimates, standard errors, and
 
F
 
 and 
 
P
 
 values from the OAB-q symptom bother
and coping subscales, respectively. Similar results
were noted in the remaining OAB-q subscales and
HRQL total score. Among the subscales, 
 
r
 
2
 
 ranged
from 0.21 (social interaction) to 0.52 (symptom
bother). The VIF was 
 
<
 
2.5 for all variables in each
model indicating the absence of multicollinearity.
The number of incontinence episodes was the
second largest contributor to HRQL impact and
symptom bother in all subscales except in the sleep
subscale where nocturia had a greater impact than
incontinence episodes. A history of bladder surgery
was the only comorbid condition that was signiﬁ-
cantly associated with each OAB-q subscale. Pros-
tate problems, diuretic use, and history of cancer
 
Table 3
 
OAB-q subscale scores by OAB status, controlled for age, sex, and comorbidities
 
Control
(n 
 
=
 
 523)
Continent OAB
(n 
 
=
 
 228)
Incontinent OAB
(n 
 
=
 
 168)
Pairwise
comparisons*
OAB-q subscale
Symptom bother
 
†
 
10.5 (0.7) 25.3 (1.2) 46.5 (1.3) All 
 
P
 
 
 
<
 
 0.0001
Coping
 
‡
 
95.8 (0.8) 87.3 (1.2) 69.3 (1.4) All 
 
P
 
 
 
<
 
 0.0001
Concern
 
‡
 
96.6 (0.7) 86.3 (1.2) 67.2 (1.3) All 
 
P
 
 
 
< 0.0001
Sleep‡ 90.6 (0.9) 77.5 (1.4) 60.8 (1.6) All P < 0.0001
Social‡ 98.9 (0.5) 95.7 (0.8) 86.6 (0.9) All P < 0.001
HRQL total‡ 95.7 (0.6) 86.7 (1.0) 70.4 (1.2) All P < 0.0001
SF-36‡
Physical function 83.2 (1.9) 75.6 (1.8) 59.0 (2.1) All P < 0.001
Role physical 82.1 (1.6) 69.9 (2.5) 49.6 (2.9) All P < 0.0001
Bodily pain 74.9 (1.1) 66.9 (1.6) 59.0 (1.9) All P < 0.01
General health 72.0 (1.0) 63.8 (1.5) 57.1 (1.7) All P < 0.01
Vitality 60.6 (0.9) 53.7 (1.4) 47.3 (1.6) All P < 0.01
Social function 87.2 (1.0) 78.8 (1.5) 71.4 (1.7) All P < 0.01
Role emotional 83.4 (1.6) 70.1 (2.4) 61.1 (2.9) All P < 0.02
Mental health 75.6 (0.8) 71.0 (1.3) 67.3 (1.4) All P < 0.05
Sleep Problems Index I† 13.3 (0.2) 15.1 (0.4) 17.2 (0.4) All P < 0.001
*Post hoc pairwise P values were not adjusted for multiple comparisons.
†Higher scores indicate greater symptom bother and greater sleep problems.
‡Higher scores indicate better HRQL.
Table 4 OAB-q subscales by presence of  sudden urge, con-
trolled for age, sex, and comorbidities
Sudden urge
(n = 369)
No sudden urge
(n = 544) P value
OAB-q subscale
Symptom bother* 32.8 (1.0) 12.4 (0.8) <0.0001
Coping† 81.3 (1.0) 94.1 (0.8) <0.0001
Concern† 80.3 (1.0) 94.5 (0.8) <0.0001
Sleep† 73.1 (1.2) 88.2 (0.9) <0.0001
Social† 92.4 (0.6) 98.1 (0.5) <0.0001
HRQL total† 81.6 (0.8) 93.8 (0.7) <0.0001
SF-36†
Physical function 73.7 (1.3) 80.1 (1.1) <0.0001
Role physical 65.4 (1.9) 79.4 (1.5) <0.0001
Bodily pain 66.2 (1.3) 73.0 (1.0) <0.0001
General health 63.1 (1.1) 70.5 (0.9) <0.0001
Vitality 52.2 (1.1) 59.5 (0.9) <0.0001
Social function 77.7 (1.2) 85.6 (1.0) <0.0001
Role emotional 67.2 (1.9) 82.1 (1.6) <0.0001
Mental health 69.6 (1.0) 75.7 (0.8) <0.0001
Sleep Problems
Index I*
15.8 (0.3) 13.4 (0.2) <0.0001
*Higher scores indicate greater symptom bother and greater sleep problems.
†Higher scores indicate better HRQL.
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were signiﬁcantly associated with the sleep subscale
whereas history of cancer was also associated with
the concern subscale. Importantly, sex, age, number
of births, diabetes, and congestive heart failure were
not signiﬁcantly associated with any OAB-q scales.
The regression models were repeated in the incon-
tinent group alone to further examine the impact of
each urinary variable among only incontinent OAB
respondents. Interestingly, urgency intensity rating
was again the most signiﬁcant urinary variable in all
models; number of incontinent episodes was not
signiﬁcant in any of the models. Nocturia was also
signiﬁcant in the sleep subscale whereas urinary fre-
quency was signiﬁcant in the coping and concern
subscales.
Discussion
Although urinary urgency and incontinence have
been associated with increases in falls and fractures
among the elderly [21], depression [22], and sleep
disturbances [23,24], the personal burden of indi-
vidual urinary symptoms on HRQL and daily activ-
ities has not been previously quantiﬁed. This
research shows that although urge incontinence has
a signiﬁcant negative impact on HRQL, the effects
of urinary frequency, urgency, and nocturia are far
from negligible. In this community sample, the
intensity of urinary urgency appears to have a far
greater impact on HRQL and symptom bother than
other OAB symptoms.
While controlling for age, sex, and multiple
comorbid conditions, the regression analyses dem-
onstrate that each symptom of OAB has a signiﬁ-
cant negative impact on HRQL and symptom
bother. Nevertheless, the analyses also clearly show
that urinary urge intensity has the strongest associ-
ation and explains the greatest variance in symptom
bother and decrements in HRQL. The number of
incontinence episodes was signiﬁcantly associated
with all OAB-q subscales; however, incontinence
did not account for the greatest variance in any
OAB-q subscale even when analyzed in the inconti-
nence group alone. This ﬁnding perhaps reﬂects the
greater importance of urinary urge intensity on
HRQL and symptom bother or may be indicative of
the inability to control urgency. Incontinent OAB
respondents reported the highest ratings of urinary
urge intensity. For incontinent OAB patients, uri-
nary urgency likely precedes the incontinent episode
and although inherently linked to incontinence, the
inability to control urgency appears to be more dis-
tressing than the incontinence itself. The effects of
Figure 1 OAB-q subscales by rating of  urge
intensity controlling for age, sex, and clinical
conditions.
0
10
20
30
40
50
60
70
80
90
100
Symptom bother Coping Concern Sleep Social interaction HRQL total
≤ 4(n = 596) 
> 4 and <8 (n =155) 
≥ 8 (n =110) 
Urge intensity rating:  * all pair-wise comparisons P < 0.0001
 all pair-wise comparisons  P < 0.01
*
* *
Table 5 OAB-q subscale scores: comparison by times uri-
nating per day (less than eight vs. eight or more), controlled for
age, sex, and comorbidities
Subscale
Less than eight
(n = 645)
Eight or more
(n = 239) P value
OAB-q subscale
Symptom bother* 18.0 (0.8) 28.0 (1.3) <0.0001
Coping† 91.7 (0.7) 81.9 (1.2) <0.0001
Concern† 91.2 (0.7) 82.2 (1.2) <0.0001
Sleep† 84.5 (0.9) 75.5 (1.5) <0.0001
Social† 97.0 (0.4) 92.8 (0.7) <0.0001
HRQL total† 91.2 (0.6) 82.8 (1.1) <0.0001
SF-36†
Physical function 78.4 (1.0) 75.7 (1.6) 0.15
Role physical 75.0 (1.4) 71.1 (2.3) 0.15
Bodily pain 71.1 (0.9) 68.2 (1.5) 0.11
General health 68.4 (0.8) 65.2 (1.3) 0.04
Vitality 57.2 (0.8) 55.1 (1.3) 0.17
Social function 83.6 (0.9) 79.2 (1.4) 0.01
Role emotional 77.5 (1.4) 74.1 (2.4) 0.22
Mental health 74.5 (0.7) 70.1 (1.2) 0.01
Sleep Problems
Index I*
14.0 (0.2) 15.3 (0.3) 0.01
*Higher scores indicate greater symptom bother and greater sleep problems.
†Higher scores indicate better HRQL.
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incontinence may be lessened or controlled to a cer-
tain extent with various preventive measures such
as the use of pads, preventive voiding, and limiting
ﬂuid intake; however, the intensity of urinary
urgency appears to be a symptom for which a
patient has little to no control.
This research does not negate the previous well-
documented ﬁndings as to the detrimental impact of
incontinence on HRQL [2–6]. In this study, incon-
tinent OAB respondents reported lower HRQL
than  continent  OAB  respondents.  These  ﬁndings
do  indicate,  however,  that  the  HRQL  impact
and symptom bother from OAB occur well before
incontinence occurs; continent OAB symptoms are
also bothersome and detrimental.
These ﬁndings provide evidence of an increased
understanding as to the impact of the multiple
symptoms of OAB. When analyzed either univari-
ately or multivariately, the OAB-q symptom bother
and HRQL subscales discriminated among people
reporting the presence or absence of multiple OAB
symptoms including urinary urgency, urinary fre-
quency, nocturia, and incontinence. Surprisingly,
age and sex were not signiﬁcantly associated with
any OAB-q subscales and the only consistent signif-
icant comorbid condition was a history of bladder
surgery. Thus, despite signiﬁcant differences in
comorbid conditions and sex among the controls
and continent and incontinent patient groups, the
symptoms of OAB accounted for the most variance
in each regression model.
The OAB-q was the most sensitive instrument in
this study in detecting differences related to partic-
ipant reports of OAB symptoms. Each symptom
was also signiﬁcantly related to other patient out-
come measures (i.e., the SF-36, the MOS-sleep
Table 6 Multivariable regression: symptom bother subscale model
Characteristic
Unstandardized
regression
coefﬁcient (b)
Standardized
regression
coefﬁcient (b) SE F value* P value
Intercept -1.14 0.0 3.36 -0.34 0.73
Age -0.03 0.02 0.04 0.45 0.50
Sex 1.01 0.02 1.55 0.43 0.51
Urinary urge intensity 2.96 0.47 0.17 297.2 <0.0001
Times urinating/day (frequency) 0.53 0.11 0.12 19.6 <0.0001
Times urinating/night (nocturia) 3.13 0.17 0.50 38.7 <0.0001
Incontinence episodes 0.16 0.19 0.02 52.1 <0.0001
Number of  births -0.06 -0.00 0.44 0.02 0.89
Diabetes 1.08 0.01 1.92 0.32 0.57
Congestive heart failure -5.21 -0.05 2.62 3.96 0.05
History of  bladder surgery 9.88 0.12 2.11 21.9 <0.0001
History of  cancer 2.48 0.03 1.89 1.73 0.19
Prostate problems 3.07 0.04 2.07 2.16 0.14
Diuretic use 2.39 0.04 1.60 2.22 0.14
*The F value represents the magnitude of  association between each independent variable and the dependent variable; the higher the F value, the stronger the association.
Model R2 = 0.52.
Table 7 Multivariable regression: OAB-q coping subscale model
Characteristic
Unstandardized
regression
coefﬁcient (b)
Standardized
regression
coefﬁcient (b) SE F value* P value
Intercept 106.9 0.0 3.50 30.53 <0.0001
Age -0.03 -0.03 0.04 0.73 0.39
Sex -1.20 -0.03 1.60 0.56 0.45
Urinary urge intensity -1.78 -0.31 0.18 97.63 <0.0001
Times urinating/day (frequency) -0.59 -0.14 0.13 21.65 <0.0001
Times urinating/night (nocturia) -1.30 -0.08 0.53 6.05 0.01
Incontinence episodes -0.18 -0.24 0.02 60.03 <0.0001
Number of  births -0.16 -0.01 0.45 0.13 0.72
Diabetes -1.66 -0.02 2.03 0.67 0.41
Congestive heart failure -3.21 -0.04 2.73 1.38 0.24
History of  bladder surgery -7.37 -0.10 2.21 11.10 0.0009
History of  cancer -3.73 -0.06 1.95 3.65 0.06
Prostate problems 0.03 0.00 2.20 0.00 0.99
Diuretic use -1.97 -0.04 1.68 1.38 0.24
*The F value represents the magnitude of  association between each independent variable and the dependent variable; the higher the F value, the stronger the association.
Model R2 = 0.35.
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scale, and the CES-D), however, to a lesser extent
than the OAB-q. This consistency in outcomes with
multiple measures provides further evidence regard-
ing the broad impact of OAB. These data also pro-
vide further support for the reliability and validity
of the OAB-q as a measure of symptom bother and
HRQL in respondents with either continent or
incontinent OAB. Internal consistency reliabilities
in this study ranged from 0.90 to 0.96 for the OAB-
q subscales. These reliabilities are comparable to
those reported in the OAB-q development and psy-
chometric evaluation study [12]. Based on recent
recommendations [25–27], psychometric evidence
is ideally needed from several independent studies
using comparable populations of people with the
target disorder to support the validity and reliability
of HRQL instruments used to support regulatory
labeling and/or promotional claims. Given the orig-
inal development study and these new data, the
OAB-q has acceptable evidence supporting its reli-
ability and validity for evaluating the impact of
OAB treatments on HRQL and symptom bother.
This research is limited in its design as a cross-
sectional survey and subject to recall bias. Many
important variables in this analysis (e.g., comorbid
conditions, bladder medications) are based entirely
on participant reports without clinical veriﬁcation.
Nevertheless, the generalizability of the results,
given the size of the community sample and diverse
geographic locations, is increased. This descriptive
analysis provides new insight on the impact of mul-
tiple urinary symptoms on HRQL.
Urinary urgency is a quantiﬁable and bothersome
symptom with signiﬁcant HRQL impact and, as
such, is a patient outcome that should not be over-
looked. Given the ﬁndings of this study, urinary
urgency and its impact merit further clinical inquiry
to ascertain whether treatments may be warranted
or desired. Additionally, given the importance of
urinary urgency on HRQL in this community sam-
ple, the impact of this symptom should be further
evaluated in a clinical setting.
The authors thank Innovative Medical Research for their
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